找回密码
 To register

QQ登录

只需一步,快速开始

扫一扫,访问微社区

Titlebook: Sphingolipid Metabolism and Metabolic Disease; Xian-Cheng Jiang Book 2022 The Editor(s) (if applicable) and The Author(s), under exclusive

[复制链接]
楼主: OAK
发表于 2025-3-25 03:23:22 | 显示全部楼层
Molecular Mechanisms of Sphingolipid Transport on Plasma Lipoproteins,ids changes in many pathological disorders, understanding mechanisms by which circulating lipoproteins assist in transporting sphingolipids may provide novel information that may help in devising strategies to therapeutically target these pathways to treat various metabolic disorders.
发表于 2025-3-25 08:11:05 | 显示全部楼层
Sphingolipid Metabolism and Signaling in Endothelial Cell Functions,golipid biosynthesis, with an emphasis on its inhibitors, ORMDL and NOGO-B. Understanding the molecular mechanisms regulating the sphingolipid de novo biosynthesis may provide the foundation for therapeutic modulation of this pathway in a variety of conditions, including cardiovascular diseases, ass
发表于 2025-3-25 15:43:40 | 显示全部楼层
发表于 2025-3-25 17:42:02 | 显示全部楼层
Sphingolipids and Asthma,is tightly regulated through feedback regulation. ORMDL3 inhibits de novo synthesis when it engages subunit 1 of the SPT complex. This chapter focuses on the effect of decreased sphingolipid synthesis on asthma features and summarizes studies in mouse models and in children with and without asthma.
发表于 2025-3-25 20:17:20 | 显示全部楼层
Manifold Roles of Ceramide Metabolism in Non-Alcoholic Fatty Liver Disease and Liver Cancer,ysregulation of the metabolism of sphingolipids contributes to development and progression of NAFLD and NAFLD-associated HCC. The present chapter summarizes roles of bioactive sphingolipids, ceramides, sphingosine, and sphingosine-1-phosphate (S1P) and their metabolizing enzymes in NAFLD and HCC.
发表于 2025-3-26 03:02:00 | 显示全部楼层
发表于 2025-3-26 08:16:51 | 显示全部楼层
Rare Diseases in Glycosphingolipid Metabolism,ave approved for treating sphingolipidoses, with some potential strategies for further evaluation. In general, enzyme replacement therapy (ERT), substrate reduction therapy (SRT), and molecular chaperones are feasible choices for enzyme deficiency disorders, but these therapies are limited to reliev
发表于 2025-3-26 11:42:59 | 显示全部楼层
Book 2022phingolipids, as well as the limitations of current research in the field, and promotes further studies on metabolic diseases, as well as pharmaceutical research on drug discovery based on sphingolipid de novo synthase.
发表于 2025-3-26 13:34:41 | 显示全部楼层
发表于 2025-3-26 18:46:58 | 显示全部楼层
 关于派博传思  派博传思旗下网站  友情链接
派博传思介绍 公司地理位置 论文服务流程 影响因子官网 SITEMAP 大讲堂 北京大学 Oxford Uni. Harvard Uni.
发展历史沿革 期刊点评 投稿经验总结 SCIENCEGARD IMPACTFACTOR 派博系数 清华大学 Yale Uni. Stanford Uni.
|Archiver|手机版|小黑屋| 派博传思国际 ( 京公网安备110108008328) GMT+8, 2025-5-22 14:01
Copyright © 2001-2015 派博传思   京公网安备110108008328 版权所有 All rights reserved
快速回复 返回顶部 返回列表